thymine has been researched along with Rectal Neoplasms in 22 studies
Rectal Neoplasms: Tumors or cancer of the RECTUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " fluoropyrimidine and irinotecan plus bevacizumab (control) as second-line treatment for metastatic colorectal cancer (mCRC)." | 9.69 | Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial. ( Hara, H; Ishihara, S; Kagawa, Y; Kajiwara, T; Kawakami, H; Kotaka, M; Kuboki, Y; Makiyama, A; Masuishi, T; Morita, S; Nakajima, TE; Nakamura, M; Ojima, H; Oki, E; Ozawa, D; Shirao, K; Sugimoto, N; Sunakawa, Y; Takashima, A; Takenaka, N; Taniguchi, H; Terazawa, T; Watanabe, J; Yoshino, T, 2023) |
| "The aim of this analysis is to assess the pharmacological costs of trifluridine/tipiracil as first-line treatment in metastatic colorectal cancer (mCRC) patients who were not candidates for combination with cytotoxic chemotherapies." | 8.12 | Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness. ( Giuliani, J, 2022) |
| "The RECOURSE trial supported trifluridine/tipiracil as a treatment option in metastatic colorectal cancer (mCRC)." | 8.12 | The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis. ( Basto, R; Bonito, N; Gomes, I; Jacinto, P; Magalhães, J; Paulo, J; Pereira, TC; Sousa, G; Sousa, MJ, 2022) |
| "Regorafenib (R) and trifluridine/tipiracil (FTD/TPI) are of proven efficacy in metastatic colorectal cancer (mCRC) patient's refractory to standard therapies." | 8.12 | Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study". ( Artru, P; Bouché, O; Coriat, R; Coutzac, C; De La Fouchardière, C; Doat, S; Gallois, C; Henriques, J; Masson, T; Moulin, V; Saint, A; Taieb, J; Tougeron, D; Trouilloud, I; Vernerey, D, 2022) |
| "The RECOURSE trial demonstrated a modest benefit in overall survival (OS) for trifluridine/tipiracil (FTD/TPI) versus placebo in pretreated metastatic colorectal cancer (mCRC) patients." | 8.12 | Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS). ( Dijksterhuis, WPM; Elferink, MAG; Hamers, PAH; Koopman, M; May, AM; Punt, CJA; Stellato, RK; Vink, GR, 2022) |
| " fluoropyrimidine and irinotecan plus bevacizumab (control) as second-line treatment for metastatic colorectal cancer (mCRC)." | 5.69 | Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial. ( Hara, H; Ishihara, S; Kagawa, Y; Kajiwara, T; Kawakami, H; Kotaka, M; Kuboki, Y; Makiyama, A; Masuishi, T; Morita, S; Nakajima, TE; Nakamura, M; Ojima, H; Oki, E; Ozawa, D; Shirao, K; Sugimoto, N; Sunakawa, Y; Takashima, A; Takenaka, N; Taniguchi, H; Terazawa, T; Watanabe, J; Yoshino, T, 2023) |
| "For patients with refractory metastatic colorectal cancer (mCRC) treatment with Trifluridine/Tipiracil, also known as TAS-102, improves overall survival." | 4.12 | Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer. ( Ananda, S; Banks, S; Dunn, C; Gard, G; Gately, L; Gibbs, P; Jalali, A; Jennens, R; Khattak, A; Kosmider, S; Lee, B; Lee, M; Lim, L; Loft, M; McKendrick, J; Shapiro, JD; Tie, J; Wong, HL; Wong, R; Yeung, JM, 2022) |
| "The aim of this analysis is to assess the pharmacological costs of trifluridine/tipiracil as first-line treatment in metastatic colorectal cancer (mCRC) patients who were not candidates for combination with cytotoxic chemotherapies." | 4.12 | Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness. ( Giuliani, J, 2022) |
| "The RECOURSE trial supported trifluridine/tipiracil as a treatment option in metastatic colorectal cancer (mCRC)." | 4.12 | The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis. ( Basto, R; Bonito, N; Gomes, I; Jacinto, P; Magalhães, J; Paulo, J; Pereira, TC; Sousa, G; Sousa, MJ, 2022) |
| "Regorafenib (R) and trifluridine/tipiracil (FTD/TPI) are of proven efficacy in metastatic colorectal cancer (mCRC) patient's refractory to standard therapies." | 4.12 | Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study". ( Artru, P; Bouché, O; Coriat, R; Coutzac, C; De La Fouchardière, C; Doat, S; Gallois, C; Henriques, J; Masson, T; Moulin, V; Saint, A; Taieb, J; Tougeron, D; Trouilloud, I; Vernerey, D, 2022) |
| "The RECOURSE trial demonstrated a modest benefit in overall survival (OS) for trifluridine/tipiracil (FTD/TPI) versus placebo in pretreated metastatic colorectal cancer (mCRC) patients." | 4.12 | Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS). ( Dijksterhuis, WPM; Elferink, MAG; Hamers, PAH; Koopman, M; May, AM; Punt, CJA; Stellato, RK; Vink, GR, 2022) |
| " The favorable safety profile of trifluridine/tipiracil renders it a suitable option to be combined with other local therapies for metastatic lesions." | 1.56 | Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report. ( Lin, BR; Lin, YL; Liu, KL, 2020) |
| " The Grade 3 or worst adverse event that was experienced was neutropenia." | 1.48 | [Safety and Efficacy of TAS-102 with Bevacizumab for the Treatment of Unresectable Metastatic Colorectal Cancer - A Case Report]. ( Arakawa, S; Asano, Y; Horiguchi, A; Imaeda, Y; Isetani, M; Ishihara, S; Ito, M; Ito, R; Kamio, K; Kawabe, N; Kawai, T; Nagata, H; Shimizu, K; Tomishige, H; Yasuoka, H, 2018) |
| " However, there are limited clinical reports of long-term administration of TAS-102." | 1.48 | [Two Cases of Long-Term Use of TAS-102 for Unresectable Colorectal Cancer]. ( Kinoshita, H; Miki, A; Nakamura, D; Sugiyama, T; Tsubono, M; Uchida, S, 2018) |
| "The possibility of interstitial pneumonitis should always be considered when a patient develops a fever and respiratory disorder during treatment containing TAS-102." | 1.48 | [A Case of Interstitial Pneumonitis Induced by TAS-102 for Liver and Lung Metastasis of Colorectal Cancer]. ( Hiramatsu, M; Imai, Y; Kobayashi, T; Kono, E; Sakane, J; Suzuki, Y; Tsunematsu, I, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.55) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.55) | 29.6817 |
| 2010's | 7 (31.82) | 24.3611 |
| 2020's | 13 (59.09) | 2.80 |
| Authors | Studies |
|---|---|
| Jalali, A | 1 |
| Gard, G | 1 |
| Banks, S | 1 |
| Dunn, C | 1 |
| Wong, HL | 1 |
| Wong, R | 1 |
| Lee, M | 1 |
| Gately, L | 1 |
| Loft, M | 1 |
| Shapiro, JD | 1 |
| Kosmider, S | 1 |
| Tie, J | 1 |
| Ananda, S | 1 |
| Yeung, JM | 1 |
| Jennens, R | 1 |
| Lee, B | 1 |
| McKendrick, J | 1 |
| Lim, L | 1 |
| Khattak, A | 1 |
| Gibbs, P | 1 |
| Schouten, JF | 1 |
| Willems, J | 1 |
| Sanders, SJWJ | 1 |
| Creemers, GJ | 1 |
| Deenen, MJ | 1 |
| Giuliani, J | 1 |
| Sousa, MJ | 1 |
| Gomes, I | 1 |
| Pereira, TC | 1 |
| Magalhães, J | 1 |
| Basto, R | 1 |
| Paulo, J | 1 |
| Jacinto, P | 1 |
| Bonito, N | 1 |
| Sousa, G | 1 |
| Coutzac, C | 1 |
| Trouilloud, I | 1 |
| Artru, P | 1 |
| Henriques, J | 1 |
| Masson, T | 1 |
| Doat, S | 1 |
| Bouché, O | 1 |
| Coriat, R | 1 |
| Saint, A | 1 |
| Moulin, V | 1 |
| Vernerey, D | 1 |
| Gallois, C | 1 |
| De La Fouchardière, C | 1 |
| Tougeron, D | 1 |
| Taieb, J | 1 |
| Hamers, PAH | 1 |
| Vink, GR | 1 |
| Elferink, MAG | 1 |
| Stellato, RK | 1 |
| Dijksterhuis, WPM | 1 |
| Punt, CJA | 1 |
| Koopman, M | 1 |
| May, AM | 1 |
| Martínez-Lago, N | 1 |
| Chucla, TC | 1 |
| De Castro, BA | 1 |
| Ponte, RV | 1 |
| Rendo, CR | 1 |
| Rodriguez, MIG | 1 |
| Diaz, SS | 1 |
| Suarez, BG | 1 |
| de la Cámara Gomez, J | 1 |
| Fernández, FB | 1 |
| Salvador, MM | 1 |
| Lopez, MR | 1 |
| Kuboki, Y | 1 |
| Terazawa, T | 1 |
| Masuishi, T | 2 |
| Nakamura, M | 1 |
| Watanabe, J | 1 |
| Ojima, H | 1 |
| Makiyama, A | 2 |
| Kotaka, M | 1 |
| Hara, H | 1 |
| Kagawa, Y | 1 |
| Sugimoto, N | 1 |
| Kawakami, H | 1 |
| Takashima, A | 2 |
| Kajiwara, T | 2 |
| Oki, E | 1 |
| Sunakawa, Y | 1 |
| Ishihara, S | 2 |
| Taniguchi, H | 1 |
| Nakajima, TE | 1 |
| Morita, S | 1 |
| Shirao, K | 1 |
| Takenaka, N | 1 |
| Ozawa, D | 1 |
| Yoshino, T | 1 |
| Shiroyama, M | 1 |
| Fukuoka, S | 1 |
| Kumekawa, Y | 1 |
| Yamazaki, K | 1 |
| Shimada, Y | 1 |
| Esaki, T | 1 |
| Moriwaki, T | 1 |
| Bolzacchini, E | 1 |
| Luchena, G | 1 |
| Giordano, M | 1 |
| Chen, J | 1 |
| Wang, J | 1 |
| Lin, H | 1 |
| Peng, Y | 1 |
| Eng, C | 1 |
| Colloca, GA | 1 |
| Venturino, A | 1 |
| Pfeiffer, P | 1 |
| Möller, S | 1 |
| Winther, SB | 1 |
| Qvortrup, C | 1 |
| Lin, YL | 1 |
| Liu, KL | 1 |
| Lin, BR | 1 |
| Arakawa, S | 1 |
| Horiguchi, A | 1 |
| Tomishige, H | 1 |
| Kawabe, N | 1 |
| Nagata, H | 1 |
| Ito, M | 1 |
| Asano, Y | 1 |
| Ito, R | 1 |
| Isetani, M | 1 |
| Shimizu, K | 1 |
| Kamio, K | 1 |
| Kawai, T | 1 |
| Yasuoka, H | 1 |
| Imaeda, Y | 1 |
| Sugiyama, T | 1 |
| Miki, A | 1 |
| Nakamura, D | 1 |
| Kinoshita, H | 1 |
| Uchida, S | 1 |
| Tsubono, M | 1 |
| Kono, E | 1 |
| Hiramatsu, M | 1 |
| Kobayashi, T | 1 |
| Tsunematsu, I | 1 |
| Imai, Y | 1 |
| Sakane, J | 1 |
| Suzuki, Y | 1 |
| Carriles, C | 1 |
| Jimenez-Fonseca, P | 1 |
| Sánchez-Cánovas, M | 1 |
| Pimentel, P | 1 |
| Carmona-Bayonas, A | 1 |
| García, T | 1 |
| Carbajales-Álvarez, M | 1 |
| Lozano-Blázquez, A | 1 |
| Saito, T | 1 |
| Mitomi, H | 1 |
| Izumi, H | 1 |
| Suehara, Y | 1 |
| Okubo, T | 1 |
| Torigoe, T | 1 |
| Takagi, T | 1 |
| Kaneko, K | 1 |
| Sato, K | 1 |
| Matsumoto, T | 1 |
| Yao, T | 1 |
| Kang, MY | 1 |
| Lee, BB | 1 |
| Ji, YI | 1 |
| Jung, EH | 1 |
| Chun, HK | 1 |
| Song, SY | 1 |
| Park, SE | 1 |
| Park, J | 1 |
| Kim, DH | 1 |
| Au, JL | 1 |
| Rustum, YM | 1 |
| Ledesma, EJ | 1 |
| Mittelman, A | 1 |
| Creaven, PJ | 1 |
1 review available for thymine and Rectal Neoplasms
| Article | Year |
|---|---|
Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Colonic Neoplasms; Colorectal Neoplasms | 2019 |
1 trial available for thymine and Rectal Neoplasms
| Article | Year |
|---|---|
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms | 2023 |
20 other studies available for thymine and Rectal Neoplasms
| Article | Year |
|---|---|
Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Colonic Neoplasms; Colorectal Neoplasms; | 2022 |
Standard-Dose Trifluridine/Tipiracil as Safe Treatment Alternative in Metastatic Colorectal Cancer Patients With DPD Deficiency.
Topics: Colonic Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Humans; Pyrrolidines; Rectal Neoplasm | 2021 |
Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms | 2022 |
The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis.
Topics: Aged; Colonic Neoplasms; Colorectal Neoplasms; Female; Humans; Liver Neoplasms; Male; Portugal; Prog | 2022 |
Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2022 |
Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2022 |
Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms | 2022 |
Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2023 |
Safety Report of TAS-102 in a Patient With Reduced DPD Activity.
Topics: Aged; Antineoplastic Agents; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase | 2019 |
TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer?
Topics: Bevacizumab; Drug Combinations; Humans; Pyrrolidines; Rectal Neoplasms; Thymine; Trifluridine; Uraci | 2020 |
TAS-102 plus bevacizumab in metastatic colorectal cancer.
Topics: Bevacizumab; Drug Combinations; Humans; Pyrrolidines; Rectal Neoplasms; Thymine; Trifluridine; Uraci | 2020 |
TAS-102 plus bevacizumab in metastatic colorectal cancer - Authors' reply.
Topics: Bevacizumab; Drug Combinations; Humans; Pyrrolidines; Rectal Neoplasms; Thymine; Trifluridine; Uraci | 2020 |
Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report.
Topics: Adenocarcinoma; Aged; Drug Combinations; Humans; Liver Neoplasms; Male; Neoplasm Staging; Peritoneal | 2020 |
[Safety and Efficacy of TAS-102 with Bevacizumab for the Treatment of Unresectable Metastatic Colorectal Cancer - A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Combinations; Humans; Liver | 2018 |
[Two Cases of Long-Term Use of TAS-102 for Unresectable Colorectal Cancer].
Topics: Aged, 80 and over; Appendiceal Neoplasms; Drug Combinations; Female; Humans; Male; Pyrrolidines; Rec | 2018 |
[A Case of Interstitial Pneumonitis Induced by TAS-102 for Liver and Lung Metastasis of Colorectal Cancer].
Topics: Aged; Drug Combinations; Humans; Liver Neoplasms; Lung Diseases, Interstitial; Lung Neoplasms; Male; | 2018 |
Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status.
Topics: Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Drug Administration Schedule; Drug Combinations; | 2019 |
A case of secondary malignant giant-cell tumor of bone with p53 mutation after long-term follow-up.
Topics: Adenocarcinoma; Arthrography; Base Sequence; Cell Transformation, Neoplastic; Cysteine; Femur; Fibro | 2011 |
Association of interindividual differences in p14ARF promoter methylation with single nucleotide polymorphism in primary colorectal cancer.
Topics: Adenine; Colonic Neoplasms; CpG Islands; Cytosine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytos | 2008 |
Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas.
Topics: Colonic Neoplasms; Drug Therapy, Combination; Floxuridine; Fluorouracil; Humans; Infusions, Parenter | 1982 |